Literature DB >> 26007213

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Erik S Musiek1, David M Holtzman1.   

Abstract

The amyloid hypothesis, which has been the predominant framework for research in Alzheimer's disease (AD), has been the source of considerable controversy. The amyloid hypothesis postulates that amyloid-β peptide (Aβ) is the causative agent in AD. It is strongly supported by data from rare autosomal dominant forms of AD. However, the evidence that Aβ causes or contributes to age-associated sporadic AD is more complex and less clear, prompting criticism of the hypothesis. We provide an overview of the major arguments for and against the amyloid hypothesis. We conclude that Aβ likely is the key initiator of a complex pathogenic cascade that causes AD. However, we argue that Aβ acts primarily as a trigger of other downstream processes, particularly tau aggregation, which mediate neurodegeneration. Aβ appears to be necessary, but not sufficient, to cause AD. Its major pathogenic effects may occur very early in the disease process.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26007213      PMCID: PMC4445458          DOI: 10.1038/nn.4018

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  134 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

4.  IKKβ deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology.

Authors:  Yang Liu; Xu Liu; Wenlin Hao; Yann Decker; Robert Schomburg; Livia Fülöp; Manolis Pasparakis; Michael D Menger; Klaus Fassbender
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 5.  Pittsburgh compound B retention and progression of cognitive status--a meta-analysis.

Authors:  X Chen; M Li; S Wang; H Zhu; Y Xiong; X Liu
Journal:  Eur J Neurol       Date:  2014-02-24       Impact factor: 6.089

6.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

Review 7.  Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis.

Authors:  Kalavathi Dasuri; Le Zhang; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2012-09-19       Impact factor: 7.376

8.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

9.  Biology and pathophysiology of the amyloid precursor protein.

Authors:  Hui Zheng; Edward H Koo
Journal:  Mol Neurodegener       Date:  2011-04-28       Impact factor: 14.195

10.  Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

Authors:  Megan E Larson; Mathew A Sherman; Susan Greimel; Michael Kuskowski; Julie A Schneider; David A Bennett; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

View more
  243 in total

1.  The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease.

Authors:  Hualong Wang; Xia Liu; Shengdi Chen; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

3.  Early Activation of Astrocytes does not Affect Amyloid Plaque Load in an Animal Model of Alzheimer's Disease.

Authors:  Dongpi Wang; Xiaoqin Zhang; Mingkai Wang; Dongming Zhou; Hongyu Pan; Qiang Shu; Binggui Sun
Journal:  Neurosci Bull       Date:  2018-07-21       Impact factor: 5.203

4.  Chronic stress impairs the aquaporin-4-mediated glymphatic transport through glucocorticoid signaling.

Authors:  Fang Wei; Jian Song; Cui Zhang; Jun Lin; Rong Xue; Li-Dong Shan; Shan Gong; Guo-Xing Zhang; Zheng-Hong Qin; Guang-Yin Xu; Lin-Hui Wang
Journal:  Psychopharmacology (Berl)       Date:  2019-01-03       Impact factor: 4.530

Review 5.  Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research.

Authors:  Michael B Dinkins; Guanghu Wang; Erhard Bieberich
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

Review 7.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

8.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

9.  Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance.

Authors:  Xiao-Dan Guo; Guang-Long Sun; Ting-Ting Zhou; Xin Xu; Zhi-Yuan Zhu; Vatcharin Rukachaisirikul; Li-Hong Hu; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

Review 10.  Developing therapeutic vaccines against Alzheimer's disease.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Expert Rev Vaccines       Date:  2015-12-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.